A major stem cell stock has received huge news this morning ( 6/30/09 ). Geron Corporation (GERN) is announcing an agreement with General Electric Co. (GE). Discuss GERN
Discuss Stocks - http://stockstobuy.org
GERN Stock News - 6/30/09
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
GE Healthcare, a unit of General Electric Company (NYSE:GE), and Geron Corporation (Nasdaq:GERN) today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. Financial terms are not being disclosed.
“This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets,” said Konstantin Fiedler, General Manager, Cell Technologies, GE Healthcare. “Combining GE Healthcare’s reach into the drug discovery and research markets, as well our expertise in cell manufacturing, with Geron’s expertise and IP in hESCs, means that together, we will be able to accelerate the development of hESC-derived products for drug discovery and development.”
Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label geron. Show all posts
Showing posts with label geron. Show all posts
Tuesday, June 30, 2009
Monday, March 9, 2009
Stem Cell Stocks 3/9/09 March 9, 2009
The following Stem Cell stocks will be higher today due to the decision from Barack Obama to overturn the block on government funding for embryonic stem cell research. White House officials said Sunday that the president's order will give the National Institutes of Health 120 days to develop ethical guidelines for the research.
Stem Cell Stocks March 9, 2009 - Pre Market
Stem Cells ( STEM ) - $2.21 Up 60.14%
Geron ( GERN ) - $5.10 Up 31.78%
Aastrom Biosciences ( ASTM ) - $0.63 Up 90.91%
Pluristem Therapeutics (PSTI) - $1.23 Up 15%
Opexa Theraputics ( OPXA ) - $0.55 Up 83.33%
Thermogenesis ( KOOL ) - $0.60 Up 49.25%
Cytori Therapeutics ( CYTX ) - $3.30 Up 42.86%
Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Baltic Dry Index
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Stem Cell Stocks March 9, 2009 - Pre Market
Stem Cells ( STEM ) - $2.21 Up 60.14%
Geron ( GERN ) - $5.10 Up 31.78%
Aastrom Biosciences ( ASTM ) - $0.63 Up 90.91%
Pluristem Therapeutics (PSTI) - $1.23 Up 15%
Opexa Theraputics ( OPXA ) - $0.55 Up 83.33%
Thermogenesis ( KOOL ) - $0.60 Up 49.25%
Cytori Therapeutics ( CYTX ) - $3.30 Up 42.86%
Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Baltic Dry Index
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Monday, January 26, 2009
Biggest Stock Gainers 1/26/09 - January 26, 2009
Today, January 26, 2009, their are several stocks gainers that are breaking out in the stock market despite the fact that we are approaching the lows for the day. Check out today's biggest gainers and the Top Stocks for 2009.
Hot Stocks 1/26/09 - Biggest Gainers Today
Barclays ( BCS ) - $4.92 Up 60.17% - Barclays stock surges after profit reassurance.
Allied Irish Banks ( AIB ) - $2.80 Up 35% - AIB is going up with the above Barclays news.
Ouiksilver ( ZQK ) - $2.07 Up 37.02% - Quiksilver stock is surging on speculation of a takeover by another company.
Geron ( GERN ) - $7.87 Up 11% - GERN continues to soar on the FDA Stem Cell News which was released Friday.
Stem Cells ( STEM ) - $2.69 Up 6.32% - STEM continues to soar on the above Geron news and is up 14 of the past 16 trading sessions. STEM has become an explosive stock and is one of 2009's Top Stock Gainers.
Other Stocks doing well - DRYS, ASTM, FCX, ING, GASS
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Hot Stocks 1/26/09 - Biggest Gainers Today
Barclays ( BCS ) - $4.92 Up 60.17% - Barclays stock surges after profit reassurance.
Allied Irish Banks ( AIB ) - $2.80 Up 35% - AIB is going up with the above Barclays news.
Ouiksilver ( ZQK ) - $2.07 Up 37.02% - Quiksilver stock is surging on speculation of a takeover by another company.
Geron ( GERN ) - $7.87 Up 11% - GERN continues to soar on the FDA Stem Cell News which was released Friday.
Stem Cells ( STEM ) - $2.69 Up 6.32% - STEM continues to soar on the above Geron news and is up 14 of the past 16 trading sessions. STEM has become an explosive stock and is one of 2009's Top Stock Gainers.
Other Stocks doing well - DRYS, ASTM, FCX, ING, GASS
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Friday, January 23, 2009
Biggest Stock Gainers 1/23/09 - January 23, 2009
Today, January 23, 2009, their are several stocks gainers that are breaking out in the stock market despite the weakness we are seeing in the major averages. Check out today's biggest gainers and the Top Stocks for 2009.
Hot Stocks 1/23/09 - Biggest Gainers
Geron ( GERN ) - $6.97 Up 33.78% - Geron received FDA Approval for the World's first clinical trial involving humans and Stem Cell Research. The CEO was on CNBC earlier in the day.
Stem Cells ( STEM ) - $2.63% Up 22% - Stem Cells is up on the above GERN news - Also up on this news is ASTM Aastom Biosciences. The Stem Cell Stocks are very hot today! We noted this yesterday!
Satyam ( SAY ) - $1.35 Up 26.16% - Satyam Board Announces Key Actions.
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Hot Stocks 1/23/09 - Biggest Gainers
Geron ( GERN ) - $6.97 Up 33.78% - Geron received FDA Approval for the World's first clinical trial involving humans and Stem Cell Research. The CEO was on CNBC earlier in the day.
Stem Cells ( STEM ) - $2.63% Up 22% - Stem Cells is up on the above GERN news - Also up on this news is ASTM Aastom Biosciences. The Stem Cell Stocks are very hot today! We noted this yesterday!
Satyam ( SAY ) - $1.35 Up 26.16% - Satyam Board Announces Key Actions.
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Geron GERN Stem Cell Stocks 1/23/09
Geron ( GERN ) is out with Stem Cell news this morning, January 23, 2009 - as this company will be the first company testing a human in the world's first human clinical trial involving Stem Cells. Under the new Obama administration, the FDA has approved this trial in which the Bush administration wasn't allowing Government funding for Stem Cell Research.
GERN stock is exploding higher today, to $6.48 Up 24%. Other Stem Cell stocks are higher such as Stem Cells ( STEM ) and Aastrom Biosciences ( ASTM )
Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The clearance enables Geron to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.
"The FDA's clearance of our GRNOPC1 IND is one of Geron's most significant accomplishments to date," said Thomas Okarma, Ph.D., M.D., Geron's president and CEO. "This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
GRNOPC1, Geron's lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
"The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury," said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. "Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year."
Full Article - http://www.geron.com/media/pressview.aspx?id=863
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
GERN stock is exploding higher today, to $6.48 Up 24%. Other Stem Cell stocks are higher such as Stem Cells ( STEM ) and Aastrom Biosciences ( ASTM )
Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The clearance enables Geron to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.
"The FDA's clearance of our GRNOPC1 IND is one of Geron's most significant accomplishments to date," said Thomas Okarma, Ph.D., M.D., Geron's president and CEO. "This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
GRNOPC1, Geron's lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
"The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury," said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. "Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year."
Full Article - http://www.geron.com/media/pressview.aspx?id=863
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Subscribe to:
Posts (Atom)
